Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
The aim of this study is to assess the effects of sibutramine (S) 15 mg/day, fluoxetine (F) 60 mg/day, and metformin (M) 1,700 mg/day, as an adjunct therapy to a 1,500 kcal/day diet, in reducing anthropometric and metabolic parameters. S (n= 8), F (n= 9), and M (n= 8) were compared to placebo (n= 10) in 35 obese patients in a 90-day trial. Side effects were also studied during the treatment. The data demonstrated that F therapy resulted in a greater average reduction in BMI (11.0%), weight (10.0%), abdominal circumference (11.0%) and %fatty-tissue (12.8). An elevation in HDL-cholesterol (25.8%) and a reduction in average triglyceride levels (28.3%) were also shown. S presented a 7.91% reduction in the abdominal circumference and a 9.65 reduction in %fatty-tissue was also found. M group presented reductions in BMI (4.03%), waist circumference (6.92%), HOMA (23.5%) and blood pressure (6.08% in systolic and 2.08% in diastolic). In general, the three drugs can be considered well tolerated. We concluded that F and S demonstrated a greater mean reduction in anthropometric and metabolic parameters when compared to M, however all of them are useful for that purpose, when the subjects characteristics are considered.
Guimarães
Camila
C
Department of Clinical, Toxicological and Bromatological Analysis, Faculty of Pharmaceutical Sciences of Ribeirão Preto.
Pereira
Leonardo R L
LR
Iucif Júnior
Nélson
N
Cesarino
Evandro José
EJ
de Almeida
Carlos A N
CA
de Carvalho
Dermeval
D
Queiroz
Regina H C
RH
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects; D001067:Appetite Depressants / Q000008:administration & dosage* / Q000009:adverse effects; D002784:Cholesterol / Q000009:adverse effects / Q000097:blood; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D010919:Placebos; D016037:Single-Blind Method
D018687:Antidepressive Agents, Second-Generation; D001067:Appetite Depressants; D003503:Cyclobutanes; D007004:Hypoglycemic Agents; D010919:Placebos; D005473:Fluoxetine; D008687:Metformin; D002784:Cholesterol; C058254:sibutramine